SGLT-2 Antibodies

Santa Cruz Biotechnology features a diverse variety of SGLT-2 monoclonal antibodies for research focused on understanding the sodium-glucose co-transporter 2 (SGLT-2) in various physiological processes. SGLT-2 Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). SGLT-2 is primarily responsible for the reabsorption of glucose in the kidneys, playing a crucial role in glucose homeostasis and energy metabolism. The significance of SGLT-2 is highlighted by its role in diabetes management, as SGLT-2 inhibitors are widely used in the treatment of type 2 diabetes mellitus. Research into SGLT-2 function and regulation continues to reveal new insights into metabolic disorders and potential therapeutic targets. Understanding SGLT-2 mechanisms can lead to improved treatment strategies for diabetes and related conditions. Investigating SGLT-2 expression patterns helps identify its role in different tissues and physiological states. SGLT-2 monoclonal antibodies from Santa Cruz Biotechnology enable researchers worldwide to advance scientific understanding of glucose transport and metabolism.